Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150328 · ClinicalTrials.gov registry record
Lenalidomide Monotherapy in R/R DLBCL
A clinical trial, sponsored by MorphoSys.
- Completed
- Registry status
- 490
- Enrollment target
NCT04150328: Completed study, sponsored by MorphoSys.
NCT04150328 is a clinical trial that has completed, run by MorphoSys. The registered enrollment target is 490 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04150328 has completed, sponsored by MorphoSys.
- COMPLETED
- Registry status
- 490 participants
- Enrollment target
Study Summary
This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
Primary Outcome
Proportion of patients with complete response (CR) or partial response (PR) as best response achieved at any time during the study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2019-04-12 |
| Est. Completion | 2020-08-25 |
What the finished NCT04150328 record still lists
NCT04150328 is an observational study that tracks outcomes without assigning an intervention. The registered 490 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT04150328 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04150328 about?
NCT04150328 is a clinical study titled "Lenalidomide Monotherapy in R/R DLBCL". This observational study is designed to characterise the effectiveness of lenalidomide monotherapy in the treatment of R/R DLBCL and to compare the results with the efficacy outcomes of a tafasitamab-lenalidomide combination therapy in the clinical trial MOR208C203 (L-MIND)
What is the current status of trial NCT04150328?
This trial is currently completed. The enrollment target is 490 participants. The study started on 2019-04-12. Estimated completion is 2020-08-25.
Who is sponsoring clinical trial NCT04150328?
This trial is sponsored by MorphoSys, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04728893 · 490 participants · Phase 2
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- NCT06238479 · 490 participants · Phase 1
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
- NCT06336928 · 490 participants
A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis
- NCT06641414 · 490 participants · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI